We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+27.29%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$6.31B
AUM Growth
+$931M
Cap. Flow
+$3.42M
Cap. Flow %
0.05%
Top 10 Hldgs %
41.19%
Holding
233
New
22
Increased
88
Reduced
44
Closed
17

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$66M
2
CRL icon
Charles River Laboratories
CRL
+$38M
3
WVE icon
Wave Life Sciences
WVE
+$20.8M
4
ABT icon
Abbott
ABT
+$19M
5
PACB icon
Pacific Biosciences
PACB
+$17.1M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$108M
2
ALDR
Alder Biopharmaceuticals
ALDR
+$84.7M
3
BOLD
Audentes Therapeutics, Inc
BOLD
+$53.2M
4
GILD icon
Gilead Sciences
GILD
+$35.4M
5
TDOC icon
Teladoc Health
TDOC
+$29.6M

Sector Composition

Rank Sector Weight
1 Healthcare 95.59%
2 Industrials 0.45%
3 Technology 0.42%
4 Communication Services 0.09%
5 Financials 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IONS icon
1
Ionis Pharmaceuticals
IONS
$8.99B
$509M 8.08%
8,431,820
+109,906
+1% +$6.55M
NBIX icon
2
Neurocrine Biosciences
NBIX
$17.2B
$357M 5.66%
3,318,374
+19,900
+0.6% +$2.08M
INCY icon
3
Incyte
INCY
$23.4B
$307M 4.87%
3,517,000
-179,200
-5% -$15.3M
VRTX icon
4
Vertex Pharmaceuticals
VRTX
$123B
$304M 4.82%
1,389,289
-39,850
-3% -$8.07M
ESPR
5
DELISTED
Esperion Therapeutics
ESPR
$270M 4.28%
4,525,010
+283,549
+7% +$12.7M
ALNY icon
6
Alnylam Pharmaceuticals
ALNY
$35.7B
$215M 3.41%
1,864,783
-100,289
-5% -$10M
AGIO icon
7
Agios Pharmaceuticals
AGIO
$2.36B
$187M 2.97%
3,924,954
+353,400
+10% +$13.4M
ARGX icon
8
argenx
ARGX
$53.8B
$156M 2.47%
967,989
-5,250
-0.5% -$710K
ALXN
9
DELISTED
Alexion Pharmaceuticals
ALXN
$150M 2.38%
1,388,928
+22,400
+2% +$2.4M
HALO icon
10
Halozyme
HALO
$9.23B
$142M 2.26%
8,036,856
+22,500
+0.3% +$390K
RDUS
11
DELISTED
Radius Health, Inc.
RDUS
$140M 2.22%
6,942,385
+65,500
+1% +$1.59M
BMY icon
12
Bristol-Myers Squibb
BMY
$124B
$134M 2.13%
2,089,242
+1,152,233
+123% +$66M
ABT icon
13
Abbott
ABT
$175B
$115M 1.83%
1,325,420
+227,306
+21% +$19M
ISRG icon
14
Intuitive Surgical
ISRG
$122B
$104M 1.65%
528,828
+1,893
+0.4% +$354K
ELV icon
15
Elevance Health
ELV
$80.9B
$98.2M 1.56%
325,174
+19,068
+6% +$5.25M
MRNA icon
16
Moderna
MRNA
$24.5B
$96.5M 1.53%
4,935,081
+91,000
+2% +$1.61M
MDT icon
17
Medtronic
MDT
$106B
$96.2M 1.53%
848,330
+40,692
+5% +$4.47M
MYOK
18
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$95.2M 1.51%
1,306,313
+13,800
+1% +$837K
SAGE
19
DELISTED
Sage Therapeutics
SAGE
$94.5M 1.5%
1,308,854
+5,350
+0.4% +$658K
ICPT
20
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$88.6M 1.41%
715,176
+13,000
+2% +$1.16M
HUM icon
21
Humana
HUM
$48B
$83.4M 1.32%
227,447
-15,226
-6% -$4.83M
ITCI
22
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$81.2M 1.29%
2,366,000
-222,990
-9% -$2.68M
UNH icon
23
UnitedHealth
UNH
$387B
$80.9M 1.28%
275,210
+36,498
+15% +$9.55M
ALGN icon
24
Align Technology
ALGN
$12.7B
$77.8M 1.23%
278,703
-59,780
-18% -$14.9M
MYOV
25
DELISTED
Myovant Sciences Ltd.
MYOV
$74.7M 1.18%
4,815,109
– –
1
2 3 4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q4 2019 Portfolio in Review

As of Q4 2019, Bellevue Group held 233 positions worth $6.31B, up 17% from $5.38B the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Bellevue Group's Q4 2019 filing shows 22 new, 88 increased, 44 reduced and 17 closed positions. Its largest new stake was Molecular Templates, Inc.: 86,379 shares worth $18.1M. The largest sale was Celgene Corp, an estimated $108M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 94% a quarter earlier, followed by Industrials and Technology.

  • Bellevue Group's largest Q4 2019 buy was Molecular Templates, Inc.: 86,379 shares worth $18.1M.
  • Bellevue Group added most to Bristol-Myers Squibb in Q4 2019, an estimated $66M increase.
  • Bellevue Group's biggest Q4 2019 reduction was Audentes Therapeutics, Inc, cutting an estimated $53.2M.
  • Bellevue Group fully exited Celgene Corp in Q4 2019, selling an estimated $108M.
  • Bellevue Group's ten largest holdings make up 41% of its $6.31B portfolio in Q4 2019.
  • Bellevue Group opened 22 new positions and closed 17 in Q4 2019.
  • Bellevue Group's portfolio value rose 17% quarter-over-quarter to $6.31B.

Based on Bellevue Group's 13F filing for Q4 2019, filed 14 Feb 2020.